Brazil state signs deal to make Russian vaccine

coronavirus
Credit: Pixabay/CC0 Public Domain

The Brazilian state of Parana signed a deal Wednesday to test and produce Russia's new coronavirus vaccine, though officials stressed they would have to be sure of its safety and effectiveness first.

The vaccine would have to receive Brazilian regulatory approval and complete Phase 3 , or in humans, before being produced in Brazil, said officials from the southern state.

Production, if it goes ahead, would likely only start in the second half of 2021, said Jorge Callado, head of the state-run Parana Technology Institute, which signed the deal with the Russian Direct Investment Fund (RDIF).

"This is a very objective memorandum of understanding on technological exchange. It does not impose obligations, it simply enables us to work together," he told a virtual news conference.

He said that under the deal Russia would share the results of Phase 1 and 2 testing with the state.

President Vladimir Putin announced Tuesday that Russia had approved the , dubbed "Sputnik V," in a world first, heralding it as a game-changer in the pandemic.

But international health officials have cautioned more testing and scrutiny are needed to ensure it is safe and effective.

Brazil has become a popular testing ground for COVID-19 vaccines, since the new coronavirus is still spreading quickly there.

The country has the second-highest number of infections and deaths in the pandemic, after the United States: more than 3.1 million and 104,000, respectively.

Two experimental vaccines are currently in Phase 3 testing in Brazil, one developed by Oxford University with pharmaceutical firm AstraZeneca and the other by Chinese laboratory Sinovac Biotech.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2020 AFP

Citation: Brazil state signs deal to make Russian vaccine (2020, August 13) retrieved 25 September 2020 from https://medicalxpress.com/news/2020-08-brazil-state-russian-vaccine.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments